Pemigatinib combined with immunotherapy and stereotactic body radiation therapy for FGFR2 fusion-positive advanced intrahepatic cholangiocarcinoma with brain metastasis: a Case Report
BackgroundFGFR2 fusions or rearrangements occur in 13%-20% of patients with intrahepatic cholangiocarcinoma (iCCA). Pemigatinib, a representative FGFR inhibitor, is commonly used for targeted therapy in such patients. Additionally, brain metastasis (BM) is extremely rare in advanced iCCA, and there...
Gardado en:
Main Authors: | , , , |
---|---|
Formato: | Libro |
Publicado: |
Frontiers Media S.A.,
2024-12-01T00:00:00Z.
|
Subjects: | |
Acceso en liña: | Connect to this object online. |
Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|
Internet
Connect to this object online.3rd Floor Main Library
Número de Clasificación: |
A1234.567 |
---|---|
Copia 1 | Dispoñible |